References
- Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105(10):4106–4114.
- Murphy M. Managing the platelet refractory patient. VOXS. 2014;9(1):234–238.
- Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337(26):1861–1869.
- Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142(3):348–360.
- Moroff G, Garratty G, Heal JM, et al. Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion. 1992;32(7):633–640.
- Rioux-Masse B, Cohn C, Lindgren B, et al. Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion. Transfusion. 2014;54(12):3080–3087.
- Stanworth SJ, Navarrete C, Estcourt L, et al. Platelet refractoriness–practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015;171(3):297–305.
- Antun AG, Gleason S, Arellano M, et al. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Cancer. 2013;119(21):3784–3787.
- Estcourt LJ, Desborough M, Brunskill SJ, et al. Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. Cochrane Database Syst Rev. 2016;3:CD009733.
- Kalmadi S, Tiu R, Lowe C, et al. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer. 2006;107(1):136–140.
- Desborough M, Estcourt LJ, Doree C, et al. Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev. 2016.
- Toh C, Hoots W, ISTH SoDICot. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5‐year overview 1. J Thromb Haemost. 2007;5(3):604–606.
- Shvidel L, Sigler E, Shtalrid M, et al. Vincristine-loaded platelet infusion for treatment of refractory autoimmune hemolytic anemia and chronic immune thrombocytopenia: rethinking old cures. Am J Hematol. 2006;81(6):423–425.
- Kerkhoffs JL, Eikenboom JC, van de Watering LM, et al. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion. 2008;48(9):1959–1965.